Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic (original) (raw)

• World Health Organization. Fact Sheet: World Malaria Report 2016 (WHO, 2016); available at http://www.who.int/malaria/media/world-malaria-report-2016/en/.
• White, N.J. et al. Malaria. Lancet 383, 723–735 (2014).
  Article PubMed Google Scholar
• Lubell, Y. et al. Artemisinin resistance--modelling the potential human and economic costs. Malar. J. 13, 452 (2014).
  Article PubMed PubMed Central Google Scholar
• Sigala, P.A. & Goldberg, D.E. The peculiarities and paradoxes of Plasmodium heme metabolism. Annu. Rev. Microbiol. 68, 259–278 (2014).
  Article CAS PubMed Google Scholar
• Combrinck, J.M. et al. Insights into the role of heme in the mechanism of action of antimalarials. ACS Chem. Biol. 8, 133–137 (2013).
  Article CAS PubMed Google Scholar
• Tilley, L., Straimer, J., Gnädig, N.F., Ralph, S.A. & Fidock, D.A. Artemisinin action and resistance in Plasmodium falciparum. Trends Parasitol. 32, 682–696 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Klonis, N. et al. Altered temporal response of malaria parasites determines differential sensitivity to artemisinin. Proc. Natl. Acad. Sci. USA 110, 5157–5162 (2013).
  Article PubMed PubMed Central Google Scholar
• Xie, S.C. et al. Haemoglobin degradation underpins the sensitivity of early ring stage Plasmodium falciparum to artemisinins. J. Cell Sci. 129, 406–416 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Dondorp, A.M. et al. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 361, 455–467 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Noedl, H. et al. Evidence of artemisinin-resistant malaria in western Cambodia. N. Engl. J. Med. 359, 2619–2620 (2008).
  Article CAS PubMed Google Scholar
• White, L.J. et al. Defining the in vivo phenotype of artemisinin-resistant falciparum malaria: a modelling approach. PLoS Med. 12, e1001823 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Saralamba, S. et al. Intrahost modeling of artemisinin resistance in Plasmodium falciparum. Proc. Natl. Acad. Sci. USA 108, 397–402 (2011).
  Article PubMed Google Scholar
• Witkowski, B. et al. Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo drug-response studies. Lancet Infect. Dis. 13, 1043–1049 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Ariey, F. et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 505, 50–55 (2014).
  Article CAS PubMed Google Scholar
• Ghorbal, M. et al. Genome editing in the human malaria parasite Plasmodium falciparum using the CRISPR–Cas9 system. Nat. Biotechnol. 32, 819–821 (2014).
  Article CAS PubMed Google Scholar
• Straimer, J. et al. K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates. Science 347, 428–431 (2015).
  Article CAS PubMed Google Scholar
• Ashley, E.A. et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 371, 411–423 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Miotto, O. et al. Genetic architecture of artemisinin-resistant Plasmodium falciparum. Nat. Genet. 47, 226–234 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Takala-Harrison, S. et al. Independent emergence of artemisinin resistance mutations among Plasmodium falciparum in Southeast Asia. J. Infect. Dis. 211, 670–679 (2015).
  Article CAS PubMed Google Scholar
• Malaria, G.E.N.P.C.P. MalariaGEN Plasmodium falciparum Community Project. Genomic epidemiology of artemisinin resistant malaria. eLife 5, e08714 (2016).
  Article Google Scholar
• Ménard, D. et al. A worldwide map of Plasmodium falciparum K13-propeller polymorphisms. N. Engl. J. Med. 374, 2453–2464 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Phyo, A.P. et al. Declining efficacy of artemisinin combination therapy against P. falciparum malaria on the Thai-Myanmar border (2003–2013): the role of parasite genetic factors. Clin. Infect. Dis. 63, 784–791 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Anderson, T.J. et al. Population parameters underlying an ongoing soft sweep in Southeast Asian malaria parasites. Mol. Biol. Evol. 34, 131–144 (2017).
  Article CAS PubMed Google Scholar
• Imwong, M. et al. The spread of artemisinin-resistant Plasmodium falciparum in the Greater Mekong subregion: a molecular epidemiology observational study. Lancet Infect. Dis. 17, 491–497 (2017).
  Article PubMed PubMed Central Google Scholar
• Lu, F. et al. Emergence of indigenous artemisinin-resistant Plasmodium falciparum in Africa. N. Engl. J. Med. 376, 991–993 (2017).
  Article PubMed Google Scholar
• Mok, S. et al. Population transcriptomics of human malaria parasites reveals the mechanism of artemisinin resistance. Science 347, 431–435 (2015).
  Article CAS PubMed Google Scholar
• Dogovski, C. et al. Targeting the cell stress response of Plasmodium falciparum to overcome artemisinin resistance. PLoS Biol. 13, e1002132 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Mbengue, A. et al. A molecular mechanism of artemisinin resistance in Plasmodium falciparum malaria. Nature 520, 683–687 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Bhattacharjee, S., Stahelin, R.V. & Haldar, K. Host targeting of virulence determinants and phosphoinositides in blood stage malaria parasites. Trends Parasitol. 28, 555–562 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Straimer, J. et al. Plasmodium falciparum K13 mutations differentially impact ozonide susceptibility and parasite fitness in vitro. mBio 8, e00172–17 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• St Laurent, B. et al. Artemisinin-resistant Plasmodium falciparum clinical isolates can infect diverse mosquito vectors of Southeast Asia and Africa. Nat. Commun. 6, 8614 (2015).
  Article CAS PubMed Google Scholar
• Uhlemann, A.C. et al. Intrahost selection of Plasmodium falciparum pfmdr1 alleles after antimalarial treatment on the northwestern border of Thailand. J. Infect. Dis. 195, 134–141 (2007).
  Article CAS PubMed Google Scholar
• Sidhu, A.B.S. et al. Decreasing pfmdr1 copy number in Plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin. J. Infect. Dis. 194, 528–535 (2006).
  Article PubMed Google Scholar
• Pascual, A. et al. In vitro piperaquine susceptibility is not associated with the Plasmodium falciparum chloroquine resistance transporter gene. Malar. J. 12, 431 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Petersen, I. et al. Balancing drug resistance and growth rates via compensatory mutations in the Plasmodium falciparum chloroquine resistance transporter. Mol. Microbiol. 97, 381–395 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Saunders, D.L., Vanachayangkul, P. & Lon, C. Dihydroartemisinin-piperaquine failure in Cambodia. N. Engl. J. Med. 371, 484–485 (2014).
  Article CAS PubMed Google Scholar
• Duru, V. et al. Plasmodium falciparum dihydroartemisinin-piperaquine failures in Cambodia are associated with mutant K13 parasites presenting high survival rates in novel piperaquine in vitro assays: retrospective and prospective investigations. BMC Med. 13, 305 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Amaratunga, C. et al. Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study. Lancet Infect. Dis. 16, 357–365 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Amato, R. et al. Genetic markers associated with dihydroartemisinin-piperaquine failure in Plasmodium falciparum malaria in Cambodia: a genotype-phenotype association study. Lancet Infect. Dis. 17, 164–173 (2017).
  Article CAS PubMed Google Scholar
• Witkowski, B. et al. A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype-genotype association study. Lancet Infect. Dis. 17, 174–183 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Dhingra, S.K. et al. A variant PfCRT isoform can contribute to Plasmodium falciparum resistance to the first-line partner drug piperaquine. MBio 8, e00303–17 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Eastman, R.T., Dharia, N.V., Winzeler, E.A. & Fidock, D.A. Piperaquine resistance is associated with a copy number variation on chromosome 5 in drug-pressured Plasmodium falciparum parasites. Antimicrob. Agents Chemother. 55, 3908–3916 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Anderson, T.J. & Roper, C. The origins and spread of antimalarial drug resistance: lessons for policy makers. Acta Trop. 94, 269–280 (2005).
  Article PubMed Google Scholar
• Trape, J.F. The public health impact of chloroquine resistance in Africa. Am. J. Trop. Med. Hyg. 64 (Suppl. 1–2), 12–17 (2001).
  Article CAS PubMed Google Scholar
• Woodrow, C.J. & White, N.J. The clinical impact of artemisinin resistance in Southeast Asia and the potential for future spread. FEMS Microbiol. Rev. 41, 34–48 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Packard, R.M. The origins of antimalarial-drug resistance. N. Engl. J. Med. 371, 397–399 (2014).
  Article CAS PubMed Google Scholar
• Eastman, R.T. & Fidock, D.A. Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. Nat. Rev. Microbiol. 7, 864–874 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Djimdé, A.A. et al. Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. Am. J. Trop. Med. Hyg. 69, 558–563 (2003).
  Article PubMed Google Scholar
• Taylor, S.M., Cerami, C. & Fairhurst, R.M. Hemoglobinopathies: slicing the Gordian knot of Plasmodium falciparum malaria pathogenesis. PLoS Pathog. 9, e1003327 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Rockett, K.A. et al. Reappraisal of known malaria resistance loci in a large multicenter study. Nat. Genet. 46, 1197–1204 (2014).
  Article CAS PubMed Central Google Scholar
• Antoine, T. et al. Rapid kill of malaria parasites by artemisinin and semi-synthetic endoperoxides involves ROS-dependent depolarization of the membrane potential. J. Antimicrob. Chemother. 69, 1005–1016 (2014).
  Article CAS PubMed Google Scholar
• Cyrklaff, M. et al. Oxidative insult can induce malaria-protective trait of sickle and fetal erythrocytes. Nat. Commun. 7, 13401 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Kavishe, R.A., Koenderink, J.B. & Alifrangis, M. Oxidative stress in malaria and artemisinin combination therapy: pros and cons. FEBS J. http://dx.doi.org/10.1111/febs.14097 (2017).
• Mbanefo, E.C. et al. Association of glucose-6-phosphate dehydrogenase deficiency and malaria: a systematic review and meta-analysis. Sci. Rep. 7, 45963 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Rathod, P.K., McErlean, T. & Lee, P.C. Variations in frequencies of drug resistance in Plasmodium falciparum. Proc. Natl. Acad. Sci. USA 94, 9389–9393 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Bopp, S.E. et al. Mitotic evolution of Plasmodium falciparum shows a stable core genome but recombination in antigen families. PLoS Genet. 9, e1003293 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Claessens, A. et al. Generation of antigenic diversity in Plasmodium falciparum by structured rearrangement of Var genes during mitosis. PLoS Genet. 10, e1004812 (2014).
  Article PubMed PubMed Central Google Scholar
• Lee, A.H. & Fidock, D.A. Evidence of a mild mutator phenotype in Cambodian Plasmodium falciparum malaria parasites. PLoS One 11, e0154166 (2016).
  Article PubMed PubMed Central Google Scholar
• Miotto, O. et al. Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. Nat. Genet. 45, 648–655 (2013).
  Article CAS PubMed Google Scholar
• Gregson, A. & Plowe, C.V. Mechanisms of resistance of malaria parasites to antifolates. Pharmacol. Rev. 57, 117–145 (2005).
  Article CAS PubMed Google Scholar
• Nair, S. et al. Adaptive copy number evolution in malaria parasites. PLoS Genet. 4, e1000243 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Kümpornsin, K. et al. Origin of robustness in generating drug-resistant malaria parasites. Mol. Biol. Evol. 31, 1649–1660 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Kateera, F. et al. Molecular surveillance of Plasmodium falciparum drug resistance markers reveals partial recovery of chloroquine susceptibility but sustained sulfadoxine-pyrimethamine resistance at two sites of different malaria transmission intensities in Rwanda. Acta Trop. 164, 329–336 (2016).
  Article CAS PubMed Google Scholar
• Fernandes, S. et al. Cost effectiveness of intermittent screening followed by treatment versus intermittent preventive treatment during pregnancy in West Africa: analysis and modelling of results from a non-inferiority trial. Malar. J. 15, 493 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Kakuru, A. et al. Dihydroartemisinin-piperaquine for the prevention of malaria in pregnancy. N. Engl. J. Med. 374, 928–939 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Maiga, H. et al. Seasonal malaria chemoprevention with sulphadoxine-pyrimethamine and amodiaquine selects pfdhfr-dhps quintuple mutant genotype in Mali. PLoS One 11, e0162718 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Yuthavong, Y. et al. Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target. Proc. Natl. Acad. Sci. USA 109, 16823–16828 (2012).
  Article PubMed PubMed Central Google Scholar
• Looareesuwan, S. et al. Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am. J. Trop. Med. Hyg. 54, 62–66 (1996).
  Article CAS PubMed Google Scholar
• Maude, R.J., Nguon, C., Dondorp, A.M., White, L.J. & White, N.J. The diminishing returns of atovaquone-proguanil for elimination of Plasmodium falciparum malaria: modelling mass drug administration and treatment. Malar. J. 13, 380 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Saunders, D.L. et al. Atovaquone-proguanil remains a potential stopgap therapy for multidrug-resistant Plasmodium falciparum in areas along the Thai-Cambodian border. Antimicrob. Agents Chemother. 60, 1896–1898 (2016).
  Article CAS PubMed Central Google Scholar
• Birth, D., Kao, W.C. & Hunte, C. Structural analysis of atovaquone-inhibited cytochrome bc1 complex reveals the molecular basis of antimalarial drug action. Nat. Commun. 5, 4029 (2014).
  Article CAS PubMed Google Scholar
• Siregar, J.E. et al. Direct evidence for the atovaquone action on the Plasmodium cytochrome bc1 complex. Parasitol. Int. 64, 295–300 (2015).
  Article CAS PubMed Google Scholar
• Painter, H.J., Morrisey, J.M., Mather, M.W. & Vaidya, A.B. Specific role of mitochondrial electron transport in blood-stage Plasmodium falciparum. Nature 446, 88–91 (2007).
  Article CAS PubMed Google Scholar
• Vaidya, A.B. Naphthoquinones: atovaquone, and other antimalarials targeting mitochondrial functions. in Treatment and Prevention of Malaria (eds. Staines, H.M. & Krishna, S.) 127–139 (Springer, Basel, 2012).
  Google Scholar
• Kuhn, S., Gill, M.J. & Kain, K.C. Emergence of atovaquone-proguanil resistance during treatment of Plasmodium falciparum malaria acquired by a non-immune north American traveller to west Africa. Am. J. Trop. Med. Hyg. 72, 407–409 (2005).
  Article PubMed Google Scholar
• Krudsood, S. et al. Efficacy of atovaquone-proguanil for treatment of acute multidrug-resistant Plasmodium falciparum malaria in Thailand. Am. J. Trop. Med. Hyg. 76, 655–658 (2007).
  Article CAS PubMed Google Scholar
• Musset, L., Le Bras, J. & Clain, J. Parallel evolution of adaptive mutations in Plasmodium falciparum mitochondrial DNA during atovaquone-proguanil treatment. Mol. Biol. Evol. 24, 1582–1585 (2007).
  Article CAS PubMed Google Scholar
• Sutherland, C.J. et al. Mutations in the Plasmodium falciparum cytochrome b gene are associated with delayed parasite recrudescence in malaria patients treated with atovaquone-proguanil. Malar. J. 7, 240 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Nixon, G.L. et al. Antimalarial pharmacology and therapeutics of atovaquone. J. Antimicrob. Chemother. 68, 977–985 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Fisher, N. et al. Cytochrome b mutation Y268S conferring atovaquone resistance phenotype in malaria parasite results in reduced parasite bc1 catalytic turnover and protein expression. J. Biol. Chem. 287, 9731–9741 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Ingasia, L.A. et al. Molecular characterization of the cytochrome b gene and in vitro atovaquone susceptibility of Plasmodium falciparum isolates from Kenya. Antimicrob. Agents Chemother. 59, 1818–1821 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Cottrell, G., Musset, L., Hubert, V., Le Bras, J. & Clain, J. Emergence of resistance to atovaquone-proguanil in malaria parasites: insights from computational modeling and clinical case reports. Antimicrob. Agents Chemother. 58, 4504–4514 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Goodman, C.D., Buchanan, H.D. & McFadden, G.I. Is the mitochondrion a good malaria drug target? Trends Parasitol. 33, 185–193 (2017).
  Article CAS PubMed Google Scholar
• Srivastava, I.K., Morrisey, J.M., Darrouzet, E., Daldal, F. & Vaidya, A.B. Resistance mutations reveal the atovaquone-binding domain of cytochrome b in malaria parasites. Mol. Microbiol. 33, 704–711 (1999).
  Article CAS PubMed Google Scholar
• Korsinczky, M. et al. Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site. Antimicrob. Agents Chemother. 44, 2100–2108 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Schwöbel, B., Alifrangis, M., Salanti, A. & Jelinek, T. Different mutation patterns of atovaquone resistance to Plasmodium falciparum in vitro and in vivo: rapid detection of codon 268 polymorphisms in the cytochrome b as potential in vivo resistance marker. Malar. J. 2, 5 (2003).
  Article PubMed PubMed Central Google Scholar
• Goodman, C.D. et al. Parasites resistant to the antimalarial atovaquone fail to transmit by mosquitoes. Science 352, 349–353 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Charman, S.A. et al. Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria. Proc. Natl. Acad. Sci. USA 108, 4400–4405 (2011).
  Article PubMed PubMed Central Google Scholar
• Siriwardana, A., Iyengar, K. & Roepe, P.D. Endoperoxide drug cross-resistance patterns for Plasmodium falciparum exhibiting an artemisinin delayed-clearance phenotype. Antimicrob. Agents Chemother. 60, 6952–6956 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Yang, T. et al. Comparison of the exposure time dependence of the activities of synthetic ozonide antimalarials and dihydroartemisinin against K13 wild-type and mutant Plasmodium falciparum strains. Antimicrob. Agents Chemother. 60, 4501–4510 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Baumgärtner, F. et al. In vitro activity of anti-malarial ozonides against an artemisinin-resistant isolate. Malar. J. 16, 45 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Phyo, A.P. et al. Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial. Lancet Infect. Dis. 16, 61–69 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Tun, K.M. et al. Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker. Lancet Infect. Dis. 15, 415–421 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Mishra, N. et al. Emerging polymorphisms in falciparum Kelch 13 gene in Northeastern region of India. Malar. J. 15, 583 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• O'Neill, P.M. et al. A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance. Nat. Commun. 8, 15159 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Li, H. et al. Structure- and function-based design of _Plasmodium_-selective proteasome inhibitors. Nature 530, 233–236 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Ng, C.L., Fidock, D.A. & Bogyo, M. Protein degradation systems as antimalarial therapeutic targets. Trends Parasitol. (in the press).
• Rottmann, M. et al. Spiroindolones, a potent compound class for the treatment of malaria. Science 329, 1175–1180 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• White, N.J. et al. Spiroindolone KAE609 for falciparum and vivax malaria. N. Engl. J. Med. 371, 403–410 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Jiménez-Díaz, M.B. et al. (+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium. Proc. Natl. Acad. Sci. USA 111, E5455–E5462 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Vaidya, A.B. et al. Pyrazoleamide compounds are potent antimalarials that target Na+ homeostasis in intraerythrocytic Plasmodium falciparum. Nat. Commun. 5, 5521 (2014).
  Article CAS PubMed Google Scholar
• Kirk, K. Ion regulation in the malaria parasite. Annu. Rev. Microbiol. 69, 341–359 (2015).
  Article CAS PubMed Google Scholar
• Spillman, N.J. et al. Na(+) regulation in the malaria parasite Plasmodium falciparum involves the cation ATPase PfATP4 and is a target of the spiroindolone antimalarials. Cell Host Microbe 13, 227–237 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• van Pelt-Koops, J.C. et al. The spiroindolone drug candidate NITD609 potently inhibits gametocytogenesis and blocks Plasmodium falciparum transmission to Anopheles mosquito vector. Antimicrob. Agents Chemother. 56, 3544–3548 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Phillips, M.A. et al. A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria. Sci. Transl. Med. 7, 296ra111 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• McCarthy, J.S. et al. Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study. Lancet Infect. Dis. 17, 626–635 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Ding, X.C., Ubben, D. & Wells, T.N. A framework for assessing the risk of resistance for anti-malarials in development. Malar. J. 11, 292 (2012).
  Article PubMed PubMed Central Google Scholar
• Hastings, I.M. & Hodel, E.M. Pharmacological considerations in the design of anti-malarial drug combination therapies - is matching half-lives enough? Malar. J. 13, 62 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Lukens, A.K. et al. Harnessing evolutionary fitness in Plasmodium falciparum for drug discovery and suppressing resistance. Proc. Natl. Acad. Sci. USA 111, 799–804 (2014).
  Article CAS PubMed Google Scholar
• Flannery, E.L. et al. Mutations in the P-type cation-transporter ATPase 4, PfATP4, mediate resistance to both aminopyrazole and spiroindolone antimalarials. ACS Chem. Biol. 10, 413–420 (2015).
  Article CAS PubMed Google Scholar
• Meister, S. et al. Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. Science 334, 1372–1377 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Kuhen, K.L. et al. KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission. Antimicrob. Agents Chemother. 58, 5060–5067 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• White, N.J. et al. Antimalarial activity of KAF156 in falciparum and vivax malaria. N. Engl. J. Med. 375, 1152–1160 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• LaMonte, G. et al. Mutations in the Plasmodium falciparum cyclic amine resistance locus (PfCARL) confer multidrug resistance. MBio 7, e00696–16 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Lim, M.Y. et al. UDP-galactose and acetyl-CoA transporters as Plasmodium multidrug resistance genes. Nat. Microbiol. 1, 16166 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Magistrado, P.A. et al. Plasmodium falciparum cyclic amine resistance locus (PfCARL), a resistance mechanism for two distinct compound classes. ACS Infect. Dis. 2, 816–826 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Paquet, T. et al. Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase. Sci. Transl. Med. 9, eaad9735 (2017).
  Article PubMed PubMed Central Google Scholar
• McNamara, C.W. et al. Targeting Plasmodium PI(4)K to eliminate malaria. Nature 504, 248–253 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Goodman, C.D., Pasaje, C.F., Kennedy, K., McFadden, G.I. & Ralph, S.A. Targeting protein translation in organelles of the Apicomplexa. Trends Parasitol. 32, 953–965 (2016).
  Article CAS PubMed Google Scholar
• Sonoiki, E. et al. A potent antimalarial benzoxaborole targets a Plasmodium falciparum cleavage and polyadenylation specificity factor homologue. Nat. Commun. 8, 14574 (2017).
  Article PubMed PubMed Central Google Scholar
• Wong, W. et al. Mefloquine targets the Plasmodium falciparum 80S ribosome to inhibit protein synthesis. Nat. Microbiol. 2, 17031 (2017).
  Article PubMed PubMed Central Google Scholar
• Baragaña, B. et al. A novel multiple-stage antimalarial agent that inhibits protein synthesis. Nature 522, 315–320 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Kato, N. et al. Diversity-oriented synthesis yields novel multistage antimalarial inhibitors. Nature 538, 344–349 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• White, N.J. Pharmacokinetic and pharmacodynamic considerations in antimalarial dose optimization. Antimicrob. Agents Chemother. 57, 5792–5807 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Daher, W. et al. Assessment of Plasmodium falciparum resistance to ferroquine (SSR97193) in field isolates and in W2 strain under pressure. Malar. J. 5, 11 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Wells, T.N. & Hooft van Huijsduijnen, R. Ferroquine: welcome to the next generation of antimalarials. Lancet Infect. Dis. 15, 1365–1366 (2015).
  Article PubMed Google Scholar
• Held, J. et al. Ferroquine and artesunate in African adults and children with Plasmodium falciparum malaria: a phase 2, multicentre, randomised, double-blind, dose-ranging, non-inferiority study. Lancet Infect. Dis. 15, 1409–1419 (2015).
  Article CAS PubMed Google Scholar
• McCarthy, J.S. et al. A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study. Malar. J. 15, 469 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Leroy, D. How to tackle antimalarial resistance? EMBO Mol. Med. 9, 133–134 (2017).
  Article CAS PubMed Google Scholar
• Plucinski, M.M. et al. Efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for treatment of uncomplicated malaria in children in Zaire and Uíge Provinces, angola. Antimicrob. Agents Chemother. 59, 437–443 (2015).
  Article CAS PubMed Google Scholar
• Corey, V.C. et al. A broad analysis of resistance development in the malaria parasite. Nat. Commun. 7, 11901 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Adjalley, S.H. et al. Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission-blocking activity by methylene blue. Proc. Natl. Acad. Sci. USA 108, E1214–E1223 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Siciliano, G. et al. A high susceptibility to redox imbalance of the transmissible stages of Plasmodium falciparum revealed with a luciferase-based mature gametocyte assay. Mol. Microbiol. 104, 306–318 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Kelly, J.X. et al. Discovery of dual function acridones as a new antimalarial chemotype. Nature 459, 270–273 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Gunsaru, B. et al. Simplified reversed chloroquines to overcome malaria resistance to quinoline-based drugs. Antimicrob. Agents Chemother. 61, e01913–16 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Vial, H. et al. CRIMALDDI: platform technologies and novel anti-malarial drug targets. Malar. J. 12, 396 (2013).
  Article PubMed PubMed Central Google Scholar
• Smith, C.M. et al. Red cells from ferrochelatase-deficient erythropoietic protoporphyria patients are resistant to growth of malarial parasites. Blood 125, 534–541 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Kesely, K.R., Pantaleo, A., Turrini, F.M., Olupot-Olupot, P. & Low, P.S. Inhibition of an erythrocyte tyrosine kinase with imatinib prevents Plasmodium falciparum egress and terminates parasitemia. PLoS One 11, e0164895 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Zumla, A. et al. Host-directed therapies for infectious diseases: current status, recent progress, and future prospects. Lancet Infect. Dis. 16, e47–e63 (2016).
  Article PubMed PubMed Central Google Scholar
• Plouffe, D.M. et al. High-throughput assay and discovery of small molecules that interrupt malaria transmission. Cell Host Microbe 19, 114–126 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• D'Alessandro, S. et al. A chemical susceptibility profile of the Plasmodium falciparum transmission stages by complementary cell-based gametocyte assays. J. Antimicrob. Chemother. 71, 1148–1158 (2016).
  Article PubMed Google Scholar
• Lucantoni, L., Fidock, D.A. & Avery, V.M. Luciferase-based, high-throughput assay for screening and profiling transmission-blocking compounds against Plasmodium falciparum gametocytes. Antimicrob. Agents Chemother. 60, 2097–2107 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Sinden, R.E. Targeting the parasite to suppress malaria transmission. Adv. Parasitol. 97, 147–185 (2017).
  Article CAS PubMed Google Scholar
• Graves, P.M., Gelband, H. & Garner, P. Primaquine or other 8-aminoquinoline for reducing Plasmodium falciparum transmission. Cochrane Database Syst. Rev. (2), CD008152 (2015).
• Ashley, E.A., Recht, J. & White, N.J. Primaquine: the risks and the benefits. Malar. J. 13, 418 (2014).
  Article PubMed PubMed Central Google Scholar
• Sundararaman, S.A. et al. Genomes of cryptic chimpanzee Plasmodium species reveal key evolutionary events leading to human malaria. Nat. Commun. 7, 11078 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Douglas, R.G., Amino, R., Sinnis, P. & Frischknecht, F. Active migration and passive transport of malaria parasites. Trends Parasitol. 31, 357–362 (2015).
  Article PubMed Google Scholar
• Seydel, K.B. et al. Brain swelling and death in children with cerebral malaria. N. Engl. J. Med. 372, 1126–1137 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Fowkes, F.J., Boeuf, P. & Beeson, J.G. Immunity to malaria in an era of declining malaria transmission. Parasitology 143, 139–153 (2016).
  Article PubMed Google Scholar
• White, N.J. Antimalarial drug resistance. J. Clin. Invest. 113, 1084–1092 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Bousema, T. & Drakeley, C. Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination. Clin. Microbiol. Rev. 24, 377–410 (2011).
  Article PubMed PubMed Central Google Scholar
• Bejon, P. et al. Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites. J. Infect. Dis. 191, 619–626 (2005).
  Article PubMed Google Scholar
• Pongtavornpinyo, W. et al. Probability of emergence of antimalarial resistance in different stages of the parasite life cycle. Evol. Appl. 2, 52–61 (2009).
  Article PubMed PubMed Central Google Scholar
• Vanaerschot, M., Huijben, S., Van den Broeck, F. & Dujardin, J.C. Drug resistance in vectorborne parasites: multiple actors and scenarios for an evolutionary arms race. FEMS Microbiol. Rev. 38, 41–55 (2014).
  Article CAS PubMed Google Scholar
• World Health Organization. Guidelines for the treatment of malaria. Third edition (WHO, 2015); available at http://www.who.int/malaria/publications/atoz/9789241549127/en/.
• Chang, C., Lin-Hua, T. & Jantanavivat, C. Studies on a new antimalarial compound: pyronaridine. Trans. R. Soc. Trop. Med. Hyg. 86, 7–10 (1992).
  Article CAS PubMed Google Scholar
• Nosten, F. & White, N.J. Artemisinin-based combination treatment of falciparum malaria. Am. J. Trop. Med. Hyg. 77 (Suppl. 6), 181–192 (2007).
  Article CAS PubMed Google Scholar
• Leang, R. et al. Efficacy of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax in Cambodia, 2008 to 2010. Antimicrob. Agents Chemother. 57, 818–826 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Ecker, A., Lehane, A.M., Clain, J. & Fidock, D.A. PfCRT and its role in antimalarial drug resistance. Trends Parasitol. 28, 504–514 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Mita, T. Origins and spread of pfdhfr mutant alleles in Plasmodium falciparum. Acta Trop. 114, 166–170 (2010).
  Article CAS PubMed Google Scholar
• Corredor, V. et al. Origin and dissemination across the Colombian Andes mountain range of sulfadoxine-pyrimethamine resistance in Plasmodium falciparum. Antimicrob. Agents Chemother. 54, 3121–3125 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Roper, C. et al. Antifolate antimalarial resistance in southeast Africa: a population-based analysis. Lancet 361, 1174–1181 (2003).
  Article PubMed Google Scholar
• Kheir, A. et al. Transmission and cross-mating of high-level resistance Plasmodium falciparum dihydrofolate reductase haplotypes in The Gambia. Am. J. Trop. Med. Hyg. 82, 535–541 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Gething, P.W. et al. A new world malaria map: Plasmodium falciparum endemicity in 2010. Malar. J. 10, 378 (2011).
  Article PubMed PubMed Central Google Scholar
• Callaghan, P.S., Hassett, M.R. & Roepe, P.D. Functional comparison of 45 naturally occurring isoforms of the Plasmodium falciparum chloroquine resistance transporter (PfCRT). Biochemistry 54, 5083–5094 (2015).
  Article CAS PubMed Google Scholar
• Pulcini, S. et al. Mutations in the Plasmodium falciparum chloroquine resistance transporter, PfCRT, enlarge the parasite's food vacuole and alter drug sensitivities. Sci. Rep. 5, 14552 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Pelleau, S. et al. Adaptive evolution of malaria parasites in French Guiana: Reversal of chloroquine resistance by acquisition of a mutation in pfcrt. Proc. Natl. Acad. Sci. USA 112, 11672–11677 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Sá, J.M. et al. Geographic patterns of Plasmodium falciparum drug resistance distinguished by differential responses to amodiaquine and chloroquine. Proc. Natl. Acad. Sci. USA 106, 18883–18889 (2009).
  Article PubMed PubMed Central Google Scholar
• Gabryszewski, S.J., Modchang, C., Musset, L., Chookajorn, T. & Fidock, D.A. Combinatorial genetic modeling of _pfcrt_-mediated drug resistance evolution in Plasmodium falciparum. Mol. Biol. Evol. 33, 1554–1570 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Sisowath, C. et al. In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa. J. Infect. Dis. 199, 750–757 (2009).
  Article CAS PubMed Google Scholar
• Conrad, M.D. et al. Comparative impacts over 5 years of artemisinin-based combination therapies on Plasmodium falciparum polymorphisms that modulate drug sensitivity in Ugandan children. J. Infect. Dis. 210, 344–353 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Venkatesan, M. et al. Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. Am. J. Trop. Med. Hyg. 91, 833–843 (2014).
  Article PubMed PubMed Central Google Scholar
• Lehane, A.M., Hayward, R., Saliba, K.J. & Kirk, K. A verapamil-sensitive chloroquine-associated H+ leak from the digestive vacuole in chloroquine-resistant malaria parasites. J. Cell Sci. 121, 1624–1632 (2008).
  Article CAS PubMed Google Scholar
• Petersen, I., Eastman, R. & Lanzer, M. Drug-resistant malaria: molecular mechanisms and implications for public health. FEBS Lett. 585, 1551–1562 (2011).
  Article CAS PubMed Google Scholar
• Lekostaj, J.K., Natarajan, J.K., Paguio, M.F., Wolf, C. & Roepe, P.D. Photoaffinity labeling of the Plasmodium falciparum chloroquine resistance transporter with a novel perfluorophenylazido chloroquine. Biochemistry 47, 10394–10406 (2008).
  Article CAS PubMed Google Scholar
• Richards, S.N. et al. Molecular mechanisms for drug hypersensitivity induced by the malaria parasite's chloroquine resistance transporter. PLoS Pathog. 12, e1005725 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Takala-Harrison, S. & Laufer, M.K. Antimalarial drug resistance in Africa: key lessons for the future. Ann. NY Acad. Sci. 1342, 62–67 (2015).
  Article CAS PubMed Google Scholar
• Lewis, I.A. et al. Metabolic QTL analysis links chloroquine resistance in Plasmodium falciparum to impaired hemoglobin catabolism. PLoS Genet. 10, e1004085 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Gabryszewski, S.J. et al. Evolution of fitness cost-neutral mutant PfCRT conferring P. falciparum 4-aminoquinoline drug resistance is accompanied by altered parasite metabolism and digestive vacuole physiology. PLoS Pathog. 12, e1005976 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Veiga, M.I. et al. Globally prevalent PfMDR1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based combination therapies. Nat. Commun. 7, 11553 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Cheeseman, I.H. et al. Population structure shapes copy number variation in malaria parasites. Mol. Biol. Evol. 33, 603–620 (2016).
  Article CAS PubMed Google Scholar
• Rosenthal, P.J. The interplay between drug resistance and fitness in malaria parasites. Mol. Microbiol. 89, 1025–1038 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Sanchez, C.P. et al. A HECT ubiquitin-protein ligase as a novel candidate gene for altered quinine and quinidine responses in Plasmodium falciparum. PLoS Genet. 10, e1004382 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Ferdig, M.T. et al. Dissecting the loci of low-level quinine resistance in malaria parasites. Mol. Microbiol. 52, 985–997 (2004).
  Article CAS PubMed Google Scholar